Top 50 Medical Startup Investors in Oceania in December 2024

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.

Right Click Capital - Australian Venture Capital Firm

Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.

Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.

Resource Capital Funds is a mining-focused alternative investments firm that partners with companies to build strong, successful, and sustainable businesses.

Investing in the deep science and technology that can propel humanity towards a radically better future.

We invest in Western Australian Innovators with bold ideas and global ambitions. We invest at Seed to Series-A in Western Australian companies.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Investing in great people solving hard problems to create a better future.

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Kurt Alexander

Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.

Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!

Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.

About NovaQuest Capital provides strategic capital to life science and healthcare companies. With experience managing over $2.75 billion of investor capital across multiple asset classes, the firm provides a robust life sciences and healthcare platform focused on promoting the development and gro...

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

At UniServices, we partner with the University of Auckland to transform ideas into real-world solutions that impact globally.

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.

Auckland University's commercialisation arm

Privately Held Companies

With origins in owning and operating Australian pharmacies, Soul Patts has evolved into a diversified investment house investing across a range of industries and asset classes, including listed equities, private equity, credit, and property.

At ArcAngels Funding, we connect female entrepreneurs across New Zealand to venture capital and investment to help their businesses grow.

Pollenizer is a co-founder of start-up web businesses in Australia. They partner with strong founders and take equity stakes at a concept stage on consumer and SaaS businesses. The skill sets cover technology, marketing and capital raising. They also occasionally make seed investments. Their businesses include;* * ** * * * * * * * * * Their team includes;* Phil Morle, ex-CTO of Kazaa, Omnidrive.* Mick Liubinskas, ex-CMO of Kazaa, Tangler, ZaprThey are also investors and partners with

CVC has seven complementary strategies across private equity, secondaries and credit, through which we invest on behalf of pension funds and other leading institutions

Great tech startup businesses are built by amazing product teams

Angeloop provides a social and business intelligence platform for Startups and Investors to leverage those networks to their full extent.

HTC Corp is engaged in the design, development, and manufacture of smartphones and tablets in Taiwan.The company offers PDA phones and smartphones for mobile operators and distributors in Europe, the United States, and Asia. These machines are available as HTC devices and as products individually customized for operators and device partners.The company provides its own HTC self-branded products as well as supports operator-branded products and original equipment manufacturer (OEM) partners. It owns Dopod as a subsidiary company and is a member of the Open Handset Alliance.The company’s products are sold under various brand names such as HTC, Dopod, and Qtek and are often rebranded by major telecommunication carriers. Its products also include pocket PC phones (PDA Phone), ultra mobile phones, HTC kovsky (Sony Ericsson XPERIA X1), and HTC dream (T-mobile G1).HTC Corp was founded by Cher Wang and Peter Chou in 1997. It is headquartered in New Taipei City, Taiwan.

SG Hiscock

We exist to serve great entrepreneurs with honest advice and education, investment capital that is fair, and an open door to our international network and connections.

Tyson & Blake We identify growth companies with unique approaches and innovative technologies that have the potential to make a profound contribution to society.We develop inspiring businesses that share our goals and our values.We create a positive impact and long-term value for our investors, the companies we invest in and the communitieswe live in.

Get Award Winning cover. Voted Outstanding Value Health Insurance for 16 Consecutive Years. Choose from flexible cover options & join online today.

Andrew R Banks

Jelix is an early-stage venture capital firm backing daring founders in Australia and New Zealand.

As Australia's national science agency and innovation catalyst, we solve the greatest challenges through innovative science and technology.

Square Peg is a global investment firm on a mission to empower exceptional founders. With investing teams in Sydney, Melbourne, Tel Aviv, and Singapore, Square Peg invests in emerging technology companies across the internet economy.